亚虹医药(688176) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was CNY 2,918,298.29, representing a year-on-year increase of 37.33%[4] - The net profit attributable to shareholders was a loss of CNY 82,610,472.36, with a year-to-date loss of CNY 268,043,612.10[4] - The basic earnings per share for the quarter was -CNY 0.14, compared to -CNY 0.47 for the same period last year[4] - The weighted average return on net assets was -3.23% for the quarter, compared to -10.15% for the same period last year[5] - The revenue for the year-to-date period was CNY 2,996,071.25, reflecting a year-on-year increase of 17,580.57%[4] - Total operating revenue for the first three quarters of 2023 reached ¥2,996,071.25, a significant increase from ¥16,945.56 in the same period of 2022[19] - Net profit for the first three quarters of 2023 was a loss of ¥268,156,193.61, worsening from a loss of ¥162,817,537.02 in the same period of 2022[20] - Basic earnings per share for the third quarter of 2023 were reported at -¥0.47, compared to -¥0.29 in the same quarter of 2022[20] Research and Development - Research and development expenses totaled CNY 69,235,698.65 for the quarter, a decrease of 11.81% compared to the previous year[5] - The company’s R&D investment accounted for 2,372.47% of its revenue, indicating a high level of investment in ongoing projects[5] - Research and development expenses for the first three quarters of 2023 totaled ¥246,139,715.41, up from ¥171,559,500.09 in 2022, indicating a year-over-year increase of about 43.5%[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,693,384,501.77, down 6.28% from the end of the previous year[5] - As of September 30, 2023, total current assets amounted to CNY 2,432,547,471.24, a decrease from CNY 2,760,086,589.05 at the end of 2022, reflecting a decline of approximately 11.87%[13] - Total liabilities as of September 30, 2023, were CNY 115,181,905.70 in current liabilities, an increase from CNY 80,664,271.29 at the end of 2022, indicating a rise of approximately 42.73%[14] - The total assets of the company were CNY 2,693,384,501.77, down from CNY 2,873,779,489.89 at the end of 2022, representing a decrease of about 6.25%[14] - The company reported a total liability of ¥175,233,749.95 as of the third quarter of 2023, an increase from ¥102,979,220.43 in the previous year[19] - The total equity attributable to shareholders of the parent company was ¥2,516,292,880.64, down from ¥2,770,800,269.46 in the same period of 2022[19] Cash Flow - The company reported a net cash flow from operating activities of -CNY 284,222,478.54 for the year-to-date period[4] - The net cash flow from operating activities for the first three quarters of 2023 was negative at ¥284,222,478.54, compared to a negative cash flow of ¥167,225,768.42 in the same period of 2022[22] - The company generated cash inflows from operating activities totaling ¥26,713,645.03 in the first three quarters of 2023, down from ¥40,128,831.33 in the previous year[22] - The net cash flow from investing activities was -$279.69 million, an improvement from -$1.72 billion in the previous year[25] - Total cash and cash equivalents at the end of the period were $491.85 million, down from $710.66 million year-over-year[25] - Cash inflow from financing activities was $33.80 million, compared to no inflow in the same period last year[25] - Cash outflow from financing activities totaled $7.79 million, a decrease from $27.71 million in the previous year[25] - The net increase in cash and cash equivalents was -$537.66 million, compared to -$1.90 billion in the prior year[25] - The company had a beginning cash balance of $1.03 billion, down from $2.61 billion year-over-year[25] Shareholder Information - The company has a total of 29,521 common shareholders as of the report date[10] - The top shareholder, PAN KE, holds 22.71% of the shares, amounting to 129,465,348 shares[10] Market and Product Updates - The company has not reported any significant new product launches or technological advancements during the quarter[12] - There are no updates on market expansion or mergers and acquisitions in the current report[12] - The company has not provided specific future guidance or performance outlook for the upcoming quarters[12] - The report indicates that there are no significant changes in the audit opinion type, remaining unaudited for this quarter[12]